Awards & Advancement

Aesica wins European Outsourcing award for UCB acquisition strategy

Thursday, November 1, 2012 10:53 AM

Aesica, a global contract manufacturing organization, has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites—at Monheim and Zwickau, Germany, and Pianezza in, Italy, in 2011.

More... »

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

arGEN-X appoints David Lacey to supervisory board

Friday, October 26, 2012 11:12 AM

arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

More... »

Former i3 CEO Bilawsky tapped to lead Precision Health Economics

Friday, October 19, 2012 02:55 PM

Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Cytos Biotechnology appoints Itin as CEO

Friday, October 12, 2012 02:29 PM

Cytos Biotechnology, a Swiss biotech company focused on the development of CYT003 in allergic asthma, has appointed Dr. Christian Itin as chief executive officer. The board of directors will propose to the company's shareholders that Itin be elected as member of the board, and it is intended that he will become chairman.

More... »

Hantash joins PharmaNet/i3

Friday, October 12, 2012 02:06 PM

PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Jamil Hantash, MSc, M.B.A., as director of Immunochemistry Operations at PharmaNet/i3’s Princeton, N.J., bioanalytical laboratory. 

More... »

PTC Therapeutics appoints Zeldis to board of directors

Thursday, October 4, 2012 12:14 PM

PTC Therapeutics, a biopharmaceutical company based in South Plainfield, N.J., has appointed Jerome B. Zeldis, M.D., Ph.D., to the company's board of directors.

More... »

Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board

Wednesday, October 3, 2012 09:39 AM

Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company's clinical advisory board. 

More... »

Third Rock Ventures names entrepreneur-in-residence

Tuesday, October 2, 2012 01:57 PM

Boston-based Third Rock Ventures, a venture capital firm focused on building life sciences companies, has named Felix W. Frueh, Ph.D., an entrepreneur-in-residence (EIR). As an EIR, Dr. Frueh will provide strategic input on new and existing portfolio companies with a particular focus on personalized medicine.

More... »